tbuckley/cabot-search huggingface dataset:
Abstract 18059: Utility of Infarct Edge Homogenization in Controlling Ventricular Tachycardia in Patients With Underlying Ischemic Heart Disease
Authors: Siva K Mulpuru, Christopher J Mcleod, Kristi H Monahan, Paul A Friedman, Douglas L Packer
Journal: Circulation (2013)

Introduction: Point source ablation may be effective in eliminating stable ventricular tachycardia (VT), where actual mapping and ablation are possible. Ablating patients with unstable VT is more complicated and may require aggressive intervention. While small linear lesions have been utilized, the actual utility of longer linear homogenization for eliminating ventricular arrhythmias has not been examined. Methods: Therefore, the results of 86 patients undergoing VT ablation at Mayo Clinic were examined. 42 had underlying ischemic heart disease with an EF of 33.5 ± 16.8 had VT with a cycle length of 326 ± 165 ms, and had 2.5± 1.6 episodes of VT in the preceding three months. 32 required shocks for that tachycardia. Results: Of these, 21 patients (16 male, 5 female Age 67±18) underwent detailed linear ablation at the scar margin in an effort to homogenize that region. This was drawn into the infarct scar by decreasing the upper voltage boundary to 2.0. In these patients, 18 showed elimination of clinical VT. In addition, 12 showed a decrease in VT from 10 ± 8.7 episodes down to 2.5 ± 1.2 episodes of actual ventricular arrhythmias. The shock requirement decreased from 8.6 ±4.7 to 1.5 ±2.7. These patients had 7 ± 3.5 different VTs at the time of ablation. These data suggest not only a decrease the occurrence of VT, but an improved control of the arrhythmia as manifested by decreased frequency of episodes and a decrease in shock. This suggests a straightforward alternative to point source ablation or to the requirement of detailed LAVA intervention. Conclusion: Linear infarct edge homogenization is a straightforward means of ablating ventricular tachycardia’s, even when unstable. This approach may be simpler than seen with LAVA interventions.
I ceppi di Staphylococcus aureus meticillino-resistenti negli ospedali tedeschi sviluppano un profilo di resistenza più limitato
Authors: W Witte, C Braulke, D Heuck, C Cuny
Journal: Eurosurveillance (2000)

La prevalenza degli Staphylococcus aureus meticillino-resistenti (MRSA) negli ospedali tedeschi continua ad aumentare, ma la gamma di antibiotici ai quali sono resistenti e diminuita. L'andamento non puo essere attribuito a cambiamenti nel consumo di antibiotici. Devono essere adottate in maniera sistematica misure di isolamento dei pazienti portatori di MRSA.
Brote de parotiditis en la provincia de León, España, 1995-1996
Authors: L. E. Visser, K. C. González Perez, J Ramos Tejera, A C Berjón Barrientos, Y Vergara Guerrero, J. F. Martinez Navarro
Journal: Eurosurveillance (1998)

La parotiditis es una enfermedad virica aguda, cuyo sintoma mas frecuente es la hinchazon dolorosa de una o ambas glandulas parotidas. La parotiditis en la infancia tiende a ser leve y alrededor del 30% de las infecciones son asintomaticas (1,2). La infeccion sistemica, que afecta a las gonadas, el pancreas y el sistema nervioso central, es mas frecuente en pacientes pospuberes.
Ferritin is secreted via 2 distinct nonclassical vesicular pathways
Authors: Marianna Truman-Rosentsvit, Dina Berenbaum, Lior Spektor, Lyora A. Cohen, Shirly Belizowsky-Moshe, Lena Lifshitz, Jing Ma, Wei Li, Ellina Kesselman, Inbal Abutbul-Ionita, Dganit Danino, Lucia Gutierrez, Huihui Li, Kuanyu Li, Huifang Lou, Maria Regoni, Maura Poli, Fabian Glaser, Tracey A. Rouault, Esther G. Meyron-Holtz
Journal: Blood (2017)
La surveillance des infections à pneumocoques en Europe
Authors: R G Pebody, W Hellenbrand, F D'Ancona, P Ruutu
Journal: Eurosurveillance (2006)

Les infections a pneumocoques (Pnc) sont responsables des infections invasives a pneumocoques – principalement la meningite et la septicemie – et representent un enjeu de sante publique important en Europe. Suite a la mise sur le marche, en Europe, d’un vaccin conjugue efficace (PCV) plusieurs pays europeens, dont la France, l’Allemagne, les Pays-Bas, la Norvege, l’Espagne et le Royaume-Uni, ont mis en place (ou sont en cours) un programme de vaccination universel contre les infections a pneumocoques chez les enfants. Dans le cadre du Pnc-EURO, projet sur les infections a pneumocoques finance par l’Union Europeenne, un questionnaire a ete envoye fin 2003 aux 25 Etats membres actuels de l’Union Europeenne, plus la Norvege et la Suisse, afin de faire le point sur la surveillance nationale des infections invasives a pneumocoques (IIP) en Europe. Tous les repondants ont ete recontactes en 2006 pour une mise a jour. Vingt-deux des 27 pays cibles ont repondu au questionnaire. Sur les 22 repondants, quatre pays n’ont pas d’obligation de declaration pour les IIP. Dix-huit pays ont declare au total 27 systemes nationaux de surveillance. Les definitions de cas variaient selon les systemes. Quatorze pays sur 18 envoient les souches d’IIP a un seul laboratoire de reference pour serotypage et 12 pays les envoient a un seul laboratoire pour les tests de sensibilite. Treize pays effectuent des controles de qualite des laboratoires. Les informations sur l’âge et le sexe sont tres generalement recueillies, mais seuls 11 systemes sur 27 collectent les informations sur le statut vaccinal par le vaccin polysaccharide et cinq sur le statut vaccinal par le vaccin conjugue. L’incidence des IIP dans les 18 pays varie de 0,4 a 20/100 000 dans la population generale, avec un total de 23 470 cas declares sur une periode de 12 mois. La surveillance des IIP en Europe est tres heterogene. Plusieurs pays manquent de systeme de surveillance. Les differences importantes dans l’incidence des cas declares peuvent etre le reflet de differences reelles, tout comme elles peuvent indiquer des variations de facteurs concernant les patients et les soins, y compris la surveillance. Si la surveillance des IIP en Europe est renforcee, les pays seront a meme de prendre des decisions documentees sur l’introduction de nouveaux vaccins contre les infections a pneumocoques et egalement de controler et comparer l’impact et l’efficacite de nouveaux programmes.
TCT-46 Prevalence of thin-cap fibroatheroma and plaque rupture in fractional flow reserve negative lesions in diabetic patients with or without acute coronary syndrome - Insights from the COMBINE Study
Authors: Balazs Berta, Tomasz Roleder, Mark Kennedy, Alexander Ijsselmuiden, Holger Nef, Javier Escaned, Fernando Alfonso, Elvin Kedhi
Journal: Journal of the American College of Cardiology (2017)
Safety of discontinuation of tyrosine kinase inhibitor therapy for patients with chronic phase CML in durable MMR: A single institution restrospective study.
Authors: James K. McCloskey, Jamie Lynn Koprivnikar, Genique Stanislaus, Stuart L. Goldberg, Stefan Faderl
Journal: Journal of Clinical Oncology (2016)

e18543 Background: Imatinib revolutionized the treatment of CML demonstrating improved survival and durable response to treatment. Earlier and deeper response rates were observed with dasatinib and nilotinib in the front line setting compared to imatinib. Multiple clinical trials have revealed that carefully selected patients may safely discontinue TKI therapy. However, lifelong TKI therapy remains the standard of care outside of clinical trial. Methods: We reviewed the charts of patients with chronic phase CML treated with imatinib, dasatinib or nilotinib for chronic phase CML between January 2010 and April 2015 and identified 29 patients that had discontinued therapy. We collected data on their treatment history, response to therapy, and outcomes following TKI withdrawal. Results: At the time of TKI cessation all the patients had achieved an MMR (MR4) for at least 2 years. The median time in MMR prior to treatment withdrawal was 64 months. Twelve patients were treated with imatinib, 7 were treated with dasatinib, and 10 were treated with nilotinib. More than half the patients had received prior treatment with an alternative TKI. At the time of data collection, 18 patients (55%) remained in MMR off therapy. The median time off treatment at was 7 months (range 3-24 months). The median time to loss of MMR was 5 months (range: 2-11 months). No significant difference was observed between TKI and time to loss of MMR. Of those patients who lost MRR while off therapy, all achieved a second MMR upon resuming TKI therapy. Based on the average wholesale price, $3,149,576 was saved by cessation of TKI therapy during the observed period. Addition follow up and PCR testing accounted for an additional cost of $84,200 for a net saving of $3,065,376. Conclusions: TKI therapy can be safely discontinued in patients with an MMR duration more than two years with close follow up. The results of this retrospective study support discontinuation of TKI therapy outside of a clinical trial. With the life expectancy of patients with chronic phase CML now approaching that of the healthy population, lifelong use of TKI has important implications for patients in terms of medical costs and quality of life.
Programmed death-1 inhibition and atherosclerosis: can nivolumab vanish complicated atheromatous plaques?
Authors: F. Gelsomino, M. Fiorentino, M. Zompatori, A. Poerio, B. Melotti, F. Sperandi, M. Gargiulo, C. Borghi, A. Ardizzoni
Journal: Annals of Oncology (2017)
TCT-128 Relationship between bioresorbable vascular scaffold technique and acute recoil
Authors: Hirofumi Hioki, Salvatore Brugaletta, Luis Ortega-Paz, Kohki Ishida, Ander Regueiro, Xavier Freixa, Victoria Martin Yuste, Monica Masotti, Manel Sabate
Journal: Journal of the American College of Cardiology (2017)
NFκB Promotes Ovarian Tumorigenesis via Classical Pathways That Support Proliferative Cancer Cells and Alternative Pathways That Support ALDH+ Cancer Stem–like Cells
Authors: Carrie D. House, Elizabeth Jordan, Lidia Hernandez, Michelle Ozaki, Jana M. James, Marianne Kim, Michael J. Kruhlak, Eric Batchelor, Fathi Elloumi, Margaret C. Cam, Christina M. Annunziata
Journal: Cancer Research (2017)

Abstract Understanding the mechanisms supporting tumor-initiating cells (TIC) is vital to combat advanced-stage recurrent cancers. Here, we show that in advanced ovarian cancers NFκB signaling via the RelB transcription factor supports TIC populations by directly regulating the cancer stem-like associated enzyme aldehyde dehydrogenase (ALDH). Loss of RelB significantly inhibited spheroid formation, ALDH expression and activity, chemoresistance, and tumorigenesis in subcutaneous and intrabursal mouse xenograft models of human ovarian cancer. RelB also affected expression of the ALDH gene ALDH1A2. Interestingly, classical NFκB signaling through the RelA transcription factor was equally important for tumorigenesis in the intrabursal model, but had no effect on ALDH. In this case, classical signaling via RelA was essential for proliferating cells, whereas the alternative signaling pathway was not. Our results show how NFκB sustains diverse cancer phenotypes via distinct classical and alternative signaling pathways, with implications for improved understanding of disease recurrence and therapeutic response. Cancer Res; 77(24); 6927–40. ©2017 AACR.
Vigilancia de la encefalitis transmitida por garrapatas en Europa y definición de caso
Authors: G Günther, L Lindquist
Journal: Eurosurveillance (2005)

El estudio realizado por P. Stefanoff y sus colegas [1] pone de manifiesto dos cuestiones importantes sobre las encefalitis transmitidas por garrapatas (ETG): la ausencia de una definicion de caso aceptada por todos, y la calidad de la vigilancia nacional de las ETG. Todos los casos declarados deberian estar confirmados y los casos clinicos relevantes con enfermedad del sistema nervioso central (SNC) deberian separarse de los casos con fiebre sin manifestaciones neurologicas. En Europa, la vigilancia de la ETG no es uniforme entre los paises y no siempre es obligatoria. Los esfuerzos para llegar a un diagnostico son variables, especialmente en las formas menos graves y en ninos, asi como tambien el conocimiento de esta enfermedad en regiones poco endemicas. La unica base estable y relevante para una vigilancia nacional son los casos que presentan enfermedad confirmada del SNC, aunque la inmunidad frente al virus tras una enfermedad febril leve pueda tener interes al nivel individual. La razon entre los casos “sin enfermedad neurologica” y “con enfermedad neurologica” es aproximadamente tres, pero existen diferencias regionales en la virulencia. Se desconoce si existen diferencias significativas asociadas a la edad.
The Dilemma of Two Innovative Therapies for Spinal Muscular Atrophy
Authors: Ans T. van der Ploeg
Journal: New England Journal of Medicine (2017)

If you have made a diagnosis of spinal muscular atrophy (SMA) type 1 (also known as Werdnig–Hoffman disease) in a child, then you have vivid memories of informing desperate parents that there is nothing you can do for their child. Two innovative therapies for SMA may now bring some hope — but what do they mean for patients and their families? SMA, which is one of the most common inheritable neuromuscular diseases, is a degenerative motor neuron disorder that leads to muscle atrophy and respiratory failure. Patients with the most severe form rarely survive beyond 2 years of age. The . . .
Urinary Incontinence in Women
Authors: Emily S. Lukacz, Yahir Santiago-Lastra, Michael E. Albo, Linda Brubaker
Journal: JAMA (2017)

<h3>Importance</h3> Urinary incontinence, the involuntary loss of urine, is a common health condition that may decrease quality of life. Ten to twenty percent of women and up to 77% of women residing in nursing homes have urinary incontinence, yet only 25% seek or receive treatment. <h3>Observations</h3> This review summarizes the evaluation and therapeutic options for women affected by urinary incontinence. The initial assessment should focus on understanding the effect of incontinence on quality of life, the patient's goals and preferences for treatment, the results of previous treatments, and the presence of concomitant conditions, such as advanced pelvic organ prolapse, that may require referral. Infection and hematuria need to be ruled out. In the absence of urinary infection or serious underlying pathology (such as cancer or serious neurologic disease) associated with urinary incontinence, the clinician should initiate unsupervised pelvic muscle exercises and lifestyle modifications appropriate to the patient to reduce her symptoms. These recommendations can include weight loss, adequate hydration, avoidance of excessive fluids, and regular voiding intervals that reduce urgency incontinence episodes. Urgency incontinence medications, with timely reassessment of symptoms, can be started without extensive evaluation. Specialist treatments for urgency incontinence include onabotulinumtoxinA and percutaneous or implanted neuromodulators. Stress incontinence surgery, the midurethral sling, is associated with symptom improvement in 48% to 90% of women and has low rates of mesh complications (&lt;5%). <h3>Conclusions and Relevance</h3> Urinary incontinence is common in women, although few seek care despite many effective treatment options. Clinicians should prioritize urinary incontinence detection, identify and treat modifiable factors, incorporate patient preference into evaluation and treatment, initiate conservative and medical therapy, and refer to specialists when underlying pathology is identified or conservative measures are ineffective.
Abstract 15801: Assessing Quality of Bystander Chest Compression and Shock Delivery by Electrocardiogram Signals From Public Automated External Defibrillators in Taiwan
Authors: Hao-Yang Lin, Hui-Chih Wang, Hsin-Lan Chu, Shu-Hsien Hsu, Weiting Chen, Nai-Wen Cheng, Edward P Huang, Matthew H Ma, Jen-Tang Sun, Wah-Sheng Chong, Ming-Ju Hsieh, Chih-Wei Yang, Kah-Meng Chong, Chih-Hao Lin, Si-Wen Hsu, Chan-Wei Kuo
Journal: Circulation (2016)

Assessing Quality of Bystander Chest Compression and Shock Delivery by Electrocardiogram Signals from Public Automated External Defibrillators in Taiwan Background: Bystander-initiated cardiopulmon...
P3.02b-045 Patritumab plus Erlotinib in EGFR Wild-Type Advanced Non–Small Cell Lung Cancer (NSCLC): Part a Results of HER3-Lung Study
Authors: Luis Paz-Arez, Piotr Serwatowski, Aleksandra Szczęsna, Joachim Von Pawel, Luca Toschi, Csőszi Tibor, Alessandro Morabito, Ling Zhang, Dale Shuster, Shuquan Chen, Catherine Copigneaux, Wallace Akerley
Journal: Journal of Thoracic Oncology (2017)
Comparative Transcriptome Analysis Quantifies Immune Cell Transcript Levels, Metastatic Progression, and Survival in Osteosarcoma
Authors: Milcah C. Scott, Nuri A. Temiz, Anne E. Sarver, Rebecca S. LaRue, Susan K. Rathe, Jyotika Varshney, Natalie K. Wolf, Branden S. Moriarity, Timothy D. O'Brien, Logan G. Spector, David A. Largaespada, Jaime F. Modiano, Subbaya Subramanian, Aaron L. Sarver
Journal: Cancer Research (2017)

Abstract Overall survival of patients with osteosarcoma (OS) has improved little in the past three decades, and better models for study are needed. OS is common in large dog breeds and is genetically inducible in mice, making the disease ideal for comparative genomic analyses across species. Understanding the level of conservation of intertumor transcriptional variation across species and how it is associated with progression to metastasis will enable us to more efficiently develop effective strategies to manage OS and to improve therapy. In this study, transcriptional profiles of OS tumors and cell lines derived from humans (n = 49), mice (n = 103), and dogs (n = 34) were generated using RNA sequencing. Conserved intertumor transcriptional variation was present in tumor sets from all three species and comprised gene clusters associated with cell cycle and mitosis and with the presence or absence of immune cells. Further, we developed a novel gene cluster expression summary score (GCESS) to quantify intertumor transcriptional variation and demonstrated that these GCESS values associated with patient outcome. Human OS tumors with GCESS values suggesting decreased immune cell presence were associated with metastasis and poor survival. We validated these results in an independent human OS tumor cohort and in 15 different tumor data sets obtained from The Cancer Genome Atlas. Our results suggest that quantification of immune cell absence and tumor cell proliferation may better inform therapeutic decisions and improve overall survival for OS patients. Significance: This study offers new tools to quantify tumor heterogeneity in osteosarcoma, identifying potentially useful prognostic biomarkers for metastatic progression and survival in patients. Cancer Res; 78(2); 326–37. ©2017 AACR.
Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients
Authors: Hervé Avet-Loiseau, Nizar J. Bahlis, Wee-Joo Chng, Tamas Masszi, Luisa Viterbo, Ludek Pour, Peter Ganly, Antonio Palumbo, Michele Cavo, Christian Langer, Andrzej Pluta, Arnon Nagler, Shaji Kumar, Dina Ben-Yehuda, S. Vincent Rajkumar, Jesus San-Miguel, Deborah Berg, Jianchang Lin, Helgi van de Velde, Dixie-Lee Esseltine, Alessandra di Bacco, Philippe Moreau, Paul G. Richardson
Journal: Blood (2017)
The effect of the Environmental Protection Agency maximum contaminant level on arsenic exposure in the USA from 2003 to 2014: an analysis of the National Health and Nutrition Examination Survey (NHANES)
Authors: Anne E Nigra, Tiffany R Sanchez, Keeve E Nachman, David E Harvey, Steven N Chillrud, Joseph H Graziano, Ana Navas-Acien
Journal: The Lancet Public Health (2017)

The current US Environmental Protection Agency (EPA) maximum contaminant level (MCL) for arsenic in public water systems (10 µg/L) took effect in 2006. Arsenic is not federally regulated in private wells. The impact of the 2006 MCL on arsenic exposure in the US, as confirmed through biomarkers, is presently unknown. We evaluated national trends in water arsenic exposure in the US, hypothesizing that urinary arsenic levels would decrease over time among participants using public water systems but not among those using well water. We further estimated the expected number of avoided lung, bladder, and skin cancer cases.We evaluated 14,127 participants in the National Health and Nutrition Examination Survey (NHANES) 2003-2014 with urinary dimethylarsinate (DMA) and total arsenic available. To isolate water exposure, we expanded a residual-based method to remove tobacco and dietary contributions of arsenic. We applied EPA risk assessment approaches to estimate the expected annual number of avoided cancer cases comparing arsenic exposure in 2013-2014 vs. 2003-2004.Among public water users, fully adjusted geometric means (GMs) of DMA decreased from 3.01 µg/L in 2003-2004 to 2.49 µg/L in 2013-2014 (17% reduction; 95% confidence interval 10%, 24%; p-trend<0.01); no change was observed among well water users (p-trend= 0.35). Assuming these estimated exposure reductions will remain similar across a lifetime, we estimate a reduction of 200 to 900 lung and bladder cancer cases per year depending on the approach used.The decline in urinary arsenic among public water but not private well users in NHANES 2003-2014 indicates that the implementation of the current MCL has reduced arsenic exposure in the US population. Our study supports prior work showing that well water users are inadequately protected against drinking water arsenic, and confirms the critical role of federal drinking water regulations in reducing toxic exposures and protecting human health.This work was supported by the National Institute of Environmental Health Sciences (1R01ES025216, R01ES021367, 5P30ES009089 and P42ES010349). A. E. Nigra was supported by 5T32ES007322.
Label-free recovery of circulating tumor cells with ClearCell® FX platform and prognostic relevance in breast cancer
Authors: Yoon Sim Yap, ManChun Leong, Garima Singh, John HengChi Lim, GuekEng Lee, Elaine Lim, Rebecca Dent, Raymond Ng, Kiley Loh, Darren Lim
Journal: Annals of Oncology (2017)
Alzheimer’s disease: A matter of blood–brain barrier dysfunction?
Authors: Axel Montagne, Zhen Zhao, Berislav V. Zlokovic
Journal: The Journal of Experimental Medicine (2017)

The blood-brain barrier (BBB) keeps neurotoxic plasma-derived components, cells, and pathogens out of the brain. An early BBB breakdown and/or dysfunction have been shown in Alzheimer's disease (AD) before dementia, neurodegeneration and/or brain atrophy occur. However, the role of BBB breakdown in neurodegenerative disorders is still not fully understood. Here, we examine BBB breakdown in animal models frequently used to study the pathophysiology of AD, including transgenic mice expressing human amyloid-β precursor protein, presenilin 1, and tau mutations, and apolipoprotein E, the strongest genetic risk factor for AD. We discuss the role of BBB breakdown and dysfunction in neurodegenerative process, pitfalls in BBB measurements, and how targeting the BBB can influence the course of neurological disorder. Finally, we comment on future approaches and models to better define, at the cellular and molecular level, the underlying mechanisms between BBB breakdown and neurodegeneration as a basis for developing new therapies for BBB repair to control neurodegeneration.